# Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer

> **NCT05930938** · PHASE3 · TERMINATED · sponsor: **Groupe Oncologie Radiotherapie Tete et Cou** · enrollment: 19 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Xevinapant
- **DRUG:** Placebo
- **DRUG:** cetuximab
- **RADIATION:** IMRT

## Key facts

- **NCT ID:** NCT05930938
- **Lead sponsor:** Groupe Oncologie Radiotherapie Tete et Cou
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-12
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** toxicity
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05930938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05930938, "Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05930938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*